Lv53
1420 积分 2023-12-04 加入
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors
5天前
已完结
PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors
5天前
已完结
A new BRAF inhibitor breaks resistance barriers
6天前
已完结
Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma
6天前
已完结
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
8天前
已完结
Physiological parameters in laboratory animals and humans
8天前
已完结
New FDA Drug Approvals for 2024: Synthesis and Clinical Application
14天前
已完结
Management of chronic myeloid leukemia in 2025
1个月前
已完结
The state of the art in secondary pharmacology and its impact on the safety of new medicines
1个月前
已完结
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
2个月前
已完结
小干扰RNA药物在慢性病领域的研究新进展：从临床前到临床
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
皖公网安备34019202002308
